GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (NAS:PRQR) » Definitions » Cyclically Adjusted Price-to-FCF

ProQR Therapeutics NV (ProQR Therapeutics NV) Cyclically Adjusted Price-to-FCF : (As of May. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ProQR Therapeutics NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF falls into.



ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

ProQR Therapeutics NV's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ProQR Therapeutics NV's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.211/128.5800*128.5800
=-0.211

Current CPI (Mar. 2024) = 128.5800.

ProQR Therapeutics NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.216 99.240 -0.280
201409 -0.756 99.960 -0.972
201412 -0.297 99.050 -0.386
201503 -0.256 99.750 -0.330
201506 -0.312 100.230 -0.400
201509 -0.304 100.500 -0.389
201512 -0.326 99.730 -0.420
201603 -0.394 100.310 -0.505
201606 -0.477 100.260 -0.612
201609 -0.539 100.570 -0.689
201612 -0.333 100.710 -0.425
201703 -0.402 101.440 -0.510
201706 -0.463 101.370 -0.587
201709 -0.359 102.030 -0.452
201712 -0.359 101.970 -0.453
201803 -0.375 102.470 -0.471
201806 -0.205 103.100 -0.256
201809 -0.152 103.950 -0.188
201812 -0.267 103.970 -0.330
201903 -0.366 105.370 -0.447
201906 -0.318 105.840 -0.386
201909 -0.249 106.700 -0.300
201912 -0.286 106.800 -0.344
202003 -0.337 106.850 -0.406
202006 -0.244 107.510 -0.292
202009 -0.237 107.880 -0.282
202012 -0.288 107.850 -0.343
202103 -0.276 108.870 -0.326
202106 -0.183 109.670 -0.215
202109 -0.142 110.790 -0.165
202112 0.056 114.010 0.063
202203 -0.320 119.460 -0.344
202206 -0.223 119.050 -0.241
202209 -0.217 126.890 -0.220
202212 -0.261 124.940 -0.269
202303 0.590 124.720 0.608
202306 -0.142 125.830 -0.145
202309 -0.103 127.160 -0.104
202312 -0.080 126.450 -0.081
202403 -0.211 128.580 -0.211

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProQR Therapeutics NV  (NAS:PRQR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV (ProQR Therapeutics NV) Business Description

Industry
Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.